Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

and Taltz and Olumiant for immunology. Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance. Where Is Eli Lilly ...

and Taltz and Olumiant for immunology. After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its ...

Alger Spectra Fund stated the following regarding Eli Lilly and Company (NYSE ... Jardiance (diabetes and obesity), Taltz (psoriasis), Emgality (migraines), and Verzenio (breast cancer).

Taltz (autoimmune diseases) at +8.3% QoQ/ +21.4% YoY, and Humalog (insulin) at +15.9% QoQ/ +69.1% YoY. These reasons are likely why LLY feels confident to offer a promising FY2025 revenue guidance ...

Eli Lilly's portfolio is somewhat diversified, with blockbuster medicines in areas such as oncology (with breast cancer medicine Verzenio) and immunology (with immunosuppressants like Taltz.